<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00541567</url>
  </required_header>
  <id_info>
    <org_study_id>S319.2.002</org_study_id>
    <secondary_id>EudraCT No. 2007-005124-32</secondary_id>
    <nct_id>NCT00541567</nct_id>
  </id_info>
  <brief_title>BMS-646256 in Obese and Overweight Type 2 Diabetics</brief_title>
  <official_title>A Placebo-Controlled, Randomized, Double-Blind, Parallel Arm, Multicenter, Dose-Ranging Phase IIb Trial to Assess Glycemic and Weight Loss Efficacy and Safety of BMS-646256 in Overweight and Obese Patients With Type 2 Diabetes Inadequately Controlled by Diet and Exercise Only or With Metformin or Sulfonylurea Monotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Solvay Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Solvay Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a placebo-controlled, randomized, double-blind, parallel arm, multicenter,
      dose-ranging phase IIb trial to assess glycemic and weight loss efficacy and safety of
      BMS-646256 in overweight and obese patients with type 2 diabetes who have been treated with
      diet and exercise only or with half-maximal or greater metformin (≥1500mg/day) or
      sulfonylurea monotherapy (stable dose for at least three months), but who remained
      inadequately controlled (HbA1c &gt;7% and HbA1c&lt;10%).
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Anticipated">June 2010</completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute change from baseline in body weight (kg) and HbA1c (%)</measure>
    <time_frame>26 weeks of double-blind therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Waist circumference, fasting glucose and insulin, HOMA analysis, blood lipids (triglycerides, total cholesterol, HDL-C, LDL-C, ApoB) and systolic/ diastolic blood pressure</measure>
    <time_frame>52 weeks treatment followed by 20 weeks off-medication period</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Obesity and Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ibipinabant</intervention_name>
    <description>oral, tablet, once daily</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 18-70 years and BMI ≥27 with type 2 diabetes who have been treated with
             diet and exercise only or with half maximal or greater metformin or sulfonylurea
             monotherapy (stable dose for at least three months), but who remained inadequately
             controlled (HbA1c &gt;7% and HbA1c&lt;10%).

        Exclusion Criteria:

          -  Pregnancy

          -  Anti-diabetic medications other than baseline metformin or sulfonylurea monotherapy

          -  History of myocardial infarction in the prior six months/ History of heart failure
             defined as New York Heart Association Functional Class I, II, III or IV/ History of
             symptomatic arrhythmia

          -  Active hepatic disease/ Any documented muscle disease

          -  History of multiple sclerosis/ Baseline history of tremors, ataxia, anxiety or
             dizziness

          -  Seizures within the last year, stroke, and transient ischemic attack/ Known history of
             schizophrenia, dementia, or bipolar disorder as defined by DSM IV criteria.

          -  Currently depressed subjects or a CES-D score greater or equal to 16 at the screening
             visit or at baseline (Day 1)/ History of suicide attempt or ideation

          -  Previous history of surgical procedures for weight loss (e.g. stomach stapling,
             bypass)/ Weight loss greater than 5 kg in the prior 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Director Solvay</last_name>
    <role>Study Director</role>
    <affiliation>Solvay Pharmaceuticals</affiliation>
  </overall_official>
  <verification_date>January 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 9, 2007</study_first_submitted>
  <study_first_submitted_qc>October 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2007</study_first_posted>
  <last_update_submitted>January 8, 2008</last_update_submitted>
  <last_update_submitted_qc>January 8, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 9, 2008</last_update_posted>
  <responsible_party>
    <name_title>Veronika von Hahn</name_title>
    <organization>Solvay Pharmaceuticals</organization>
  </responsible_party>
  <keyword>Wheight management in T2D</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibipinabant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

